Motor fluctuations and dyskinesias occur in a large proportion of APD patients with disease duration of 10 years or more. However, only 10% are reported to experience severe ON-OFF fluctuations and would be therefore eligible for treatment with LCIG, that is, approximately 1% of all PD patients. An OFF episode is when medication wears off and is no longer effective. During an OFF episode, the patient experiences heightened tremors and other symptoms which are often disabling and distressing leaving the patient stiff and slow. OFF episodes can be predicable or spontaneous. An ON period is when the treatment is working and the patient experiences an improvement in their PD symptoms 17 . Patients typically begin experiencing OFF periods around five years after starting treatment 17 . Eventually, advanced PD leads to confinement of the patient to a bed or wheelchair 4 . LCIG has received the EMA orphan drug status due to its very limited patient population, facing a severely disabling disease and high unmet medical need
18
. There are no published studies reporting the economic value of LCIG in treatment of patients with APD in Ireland.
OBJECTIVES
Determine the cost-effectiveness of LCIG compared with Standard of Care (SoC) for the treatment of APD patients in Ireland using a Markov model.
METHODS

Model structure
The LCIG cost-effectiveness model is a Markov model with 6 month cycles. The model redistributes the population into disease-specific health states based on the impact of treatment with LCIG on the natural history of disease progression. Patients were deterministically tracked through the different health states over time, accumulating costs and benefits (health state utilities) while in each health state. The costeffectiveness of LCIG was estimated relative to SoC in treatment of advanced PD with severe motor fluctuations and is presented in terms of the incremental cost per quality adjusted life year (QALY) gained.
Health states
The health states were defined by Hoehn and Yahr (H&Y) • OFF 0: 0%
• OFF 1: 1 -25%
• OFF II: 26-50%
• OFF III: 51-75% and
• OFF IV: 76-100%.
The model comprises 26 health states in total, 25 PD health states plus death. Figure 1 shows the model structure. Patients can only progress through consecutive H&Y and OFF states. Death can be reached from any state. 
Patient cohort
Patients included in the model are advanced PD patients with severe motor fluctuations defined as H&Y >3 and OFF time > 50%. The distribution of patients across these health states at entry into the model is based on the distribution observed at baseline in the S187-3-004 6 study: HY 3-OFF III: 62%, HY 3-OFF IV: 3%, HY 4-OFF III: 32%, HY 4-OFF IV: 3%, HY 5-OFF III: 0%, HY 5-OFF IV: 0%. The LCIG cohort enters the model with an average of 64 years and a gender distribution of 59% male.
For the SoC arm, a hypothetical cohort was created to mirror the baseline LCIG cohort.
Comparators
To reflect current clinical practice in Ireland and patient distribution at any given time, SoC was assumed to include conventional oral PD medication (for example levodopa, 2 nd generation dopamine agonists, COMT inhibitors) ± sub-cutaneous apomorphine infusion and standard follow-up visits. The casemix for SoC in the present analysis was 91.8% conventional or PD medication and 8.2% subcutaneous apomorphine infusion and was based on medication utilization observed in Adelphi 5 . 
METHODS (CONTINUED)
Perspective and time horizon
The model takes the healthcare perspective, HSE/Payer in Ireland, therefore includes direct medical costs and direct non-medical costs only.
The time horizon of the analysis is 20 years and patients are followed until death if it occurs prior to 20 years. This time horizon approximates lifetime treatment and is relevant to the payer as treatment for advanced PD is chronic.
Health state transition probabilities
The H&Y stage transition probabilities were obtained from Johnson et al. 9 As each cycle in the present model is 6 months, the monthly transition probabilities reported in Johnson et al. 9 were adjusted using an exponential function to obtain the per cycle probability.
The model assumes that patients can progress from one H&Y stage to the next more severe one, but cannot progress more than one stage within a single cycle, as it is clinically unlikely they would do so within a 6 month period.
The transition probabilities for OFF states were based on information obtained from Palmer et al. 10, 11 and updated through simple regression techniques. 
Medication and treatment-related costs
Treatment related and PD medication costs for LCIG and SoC patients were obtained from publicly available costs, based on 2011 data 15 . In cases where the Irish costs were not available due to the product been discontinued or for other reasons, UK costs have been converted to € using the most recent available exchange rate and these were based on the NHS National Schedule of Reference Costs (Year 2011-12) NHS trusts and NHS foundation trusts.
The medication costs can be seen in Table 2 and the medical resource costs can be seen in Table 3 
Health states utilities
The utility weights applied to each of the 25 health states in the model were estimated from a regression equation Combining the EQ-5D data from these studies allowed an increase in the sample size for more severe health states, which in turn improves the precision of the estimation of the utility in these states. 
CLINICAL INPUTS
LCIG treatment effect
The treatment effect of LCIG is modelled based on its initial treatment effect (effectiveness on improving H&Y stage and OFF state in the first 12 months of treatment) and maintenance of the LCIG initial treatment effect on OFF time over the long term (> 12 months). The initial treatment effect is based on the results from study S187-3-004 6 . The LCIG OFF time maintenance effect is based on the results from study DAPHNE 7 which showed that the initial benefits in improved OFF time are maintained during long-term treatment with LCIG (up to 9 years). Given that PD is progressive and incurable, it is assumed that LCIG has no effect on the progression through H&Y stages in the long-term.
Device complications
Only device complications resulting in resource utilization from LCIG treatment are considered in the model. Complications associated with SoC are not considered. This is a conservative approach as we would anticipate that some of the medications contained within the SoC regimen would result in resource-incurring complications.
Discontinuation rates
For the first 12 months (in which LCIG patients may experience benefit), discontinuation rates were calculated separately for cycles 1 and 2 using the 1 year follow-up data from Study S187-3-004 6 as 6.8%. For the longterm treatment effect (cycles 3+) the discontinuation was obtained from a recently published long term LCIG follow-up study, Nyholm et al 13 as 1.4%.
Mortality
Mortality is accounted for in the model using all-cause mortality probabilities from the most recent available Irish Life Tables 12 .
Discount rates
Costs and outcomes are discounted at 4% (as per Irish HTA guidelines 14 ).
Analysis of uncertainty
One-way sensitivity analyses (OWSA) were carried out in order to identify the key drivers of cost-effectiveness. Probabilistic sensitivity analysis (PSA) was performed with the intention of testing the overall robustness of the model. The key parameters varied in the OWSA were long-term efficacy, heath state costs, medication costs, discount rates and cassette use. The PSA was conducted through repeated sampling of mean parameter values from a series of assigned distribution types.
RESULTS
The output for base-case analysis can be seen in table below. The ICER is below the willingness to pay (WTP) threshold in Ireland of €45,000/QALY. The tornado diagram from the OWSA can be seen in Figure 2 . The key drivers of cost-effectiveness are health state costs, LCIG cassette use and the long-term effect of LCIG on OFF time.
Uncertainty around the estimates of incremental cost-effectiveness based on the PSA are presented as a cost-effectiveness acceptability curve (CEAC) and can be seen in Figure 3 . The CEAC for LCIG indicates that at WTP threshold of €45,000, there is a 42% probability of LCIG being considered as cost-effective under the current probabilistic assumptions. 
